Monopar Therapeutics (NASDAQ:MNPR) Shares Up 3.1% - What's Next?

Key Points

• Monopar Therapeutics shares rose 3.1% to $82.04 during mid-day trading, although volume was 90% below the average daily level.
• Analyst sentiment remains positive overall, with an average “Moderate Buy” rating and a $122 target price; Barclays recently raised its target to $145.
• The clinical-stage cancer biotechnology company beat quarterly EPS expectations, reporting a loss of $0.62 per share versus the estimated $0.64 loss, while insiders sold $4.0 million of stock over the past three months.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report)'s stock price was up 3.1% during mid-day trading on Wednesday. The stock traded as high as $82.32 and last traded at $82.04. 20,994 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 210,178 shares. The stock had previously closed at $79.57.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MNPR. Barclays reiterated an "overweight" rating and set a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. HC Wainwright raised their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a report on Wednesday, July 22nd. Morgan Stanley reaffirmed an "overweight" rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday, August 17th. Zacks Research downgraded shares of Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 13th. Finally, Cantor Fitzgerald cut shares of Monopar Therapeutics from an "overweight" rating to a "neutral" rating and raised their target price for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $122.00.

Monopar Therapeutics Stock Up 6.6%

The firm has a market cap of $569.18 million, a price-to-earnings ratio of -39.09 and a beta of 1.50. The stock has a 50 day moving average of $106.02 and a 200 day moving average of $83.16.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. As a group, analysts predict that Monopar Therapeutics Inc. will post -2.98 EPS for the current fiscal year.

Insider Activity

In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of the business's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the transaction, the director owned 23,751 shares of the company's stock, valued at approximately $2,654,649.27. The trade was a 11.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the firm's stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the completion of the sale, the chief executive officer owned 99,267 shares in the company, valued at approximately $8,735,496. The trade was a 22.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,688 shares of company stock valued at $4,023,094 in the last three months. Company insiders own 9.70% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MNPR. Sei Investments Co. boosted its stake in shares of Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company's stock valued at $415,000 after purchasing an additional 656 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $86,000. Your Advocates Ltd. LLP acquired a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $183,000. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics in the 1st quarter valued at approximately $250,000. Finally, Virtu Financial LLC bought a new stake in Monopar Therapeutics during the 4th quarter worth approximately $654,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company's research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar's portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.